Oxford Biomedica (LON:OXB) Announces Earnings Results

Oxford Biomedica (LON:OXB) posted its earnings results on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%.

Oxford Biomedica Stock Performance

OXB stock traded up GBX 2.50 ($0.03) during trading on Friday, hitting GBX 281 ($3.65). 78,525 shares of the company traded hands, compared to its average volume of 305,644. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. Oxford Biomedica has a 1 year low of GBX 187.83 ($2.44) and a 1 year high of GBX 455 ($5.91). The stock’s 50-day simple moving average is GBX 319.38 and its 200 day simple moving average is GBX 379.08. The company has a market cap of £298.71 million, a PE ratio of -2.09 and a beta of 1.09.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.